A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-13 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
== Synaptic plasticity == AMPA receptors (AMPAR) are both glutamate receptors and cation channels that are integral to plasticity and synaptic transmission at many postsynaptic membranes. One of the most widely and thoroughly investigated forms of plasticity in the nervous system is known as long-term potentiation (LTP). There are two necessary components of LTP: presynaptic glutamate release and postsynaptic depolarization. Therefore, LTP can be induced experimentally in a paired electrophysiological recording when a presynaptic cell is stimulated to release glutamate on a postsynaptic cell that is depolarized. The typical LTP induction protocol involves a "tetanus" stimulation, which is a 100-Hz stimulation for 1 second. When one applies this protocol to a pair of cells, one will see a sustained increase of the amplitude of the excitatory postsynaptic potential (EPSP) following tetanus. This response is interesting because it is thought to be the physiological correlation for learning and memory in the cell. In fact, it has been shown that, following a single paired-avoidance paradigm in mice, LTP can be recorded in some hippocampal synapses in vivo. The molecular basis for LTP has been extensively studied, and AMPARs have been shown to play an integral role in the process. Both GluR1 and GluR2 play an important role in synaptic plasticity.
In column chromatography a mixture of substances is dissolved in a mobile phase and passed over a stationary phase in a column. A selectivity factor is defined as the ratio of distribution coefficients, which describe the equilibrium distribution of an analyte between the stationary phase and the mobile phase. The selectivity factor is equal to the selectivity coefficient with the added assumption that the activity of the stationary phase, the substrate in this case, is equal to 1, the standard assumption for a pure phase. The resolution of a chromatographic column, RS is related to the selectivity factor by:
==== Early 2000s ==== In 2000, both Hird and the Essendon Football Club experienced the most dominant season in AFL football to date. Injury-free, he received numerous honours, including selection in the All-Australian team and the Norm Smith Medal as best on ground in the AFL Grand Final. The Essendon team also won the Ansett Cup pre-season competition as well as the regular season premiership. The team only lost one game — against the Western Bulldogs—in the entire calendar year. The year 2002 then saw Hird's worst injury, a horrific facial injury sustained in a match against Fremantle when he collided with teammate Mark McVeigh's knee, fracturing several bones; Hird was in hospital for a week and missed several weeks of the season. In 2003, despite again missing many games through various injuries (eight games in total), Hird tied with Scott Lucas for the best-and-fairest award. He also narrowly missed out on a second Brownlow Medal, finishing three votes shy of joint winners Mark Ricciuto, Nathan Buckley and Adam Goodes. He gained a place in the 2003 All-Australian team, the fifth and final time in his career. One of Hird's more memorable performances was in his Round 3 game against West Coast in 2004. Up until three-quarter time, Hird had 19 disposals and one goal; in the final quarter, however, he managed 15 disposals and two decisive goals.
== Applications == Development of solid lipid nanoparticles is one of the fields of lipid nanotechnology (for a review on lipid nanotechnology, see ) with several potential applications in drug delivery, clinical medicine and research, as well as in other disciplines. Due to their size-dependent properties, lipid nanoparticles can possibly develop new therapeutics. The ability to incorporate drugs into nanocarriers offers a new prototype in drug delivery that could hold great promise for attaining bioavailability enhancement along with controlled and site-specific drug delivery. SLNs are also considered to be well tolerated in general, due to their composition from physiologically similar lipids. The conventional approaches such as use of permeation enhancers, surface modification, prodrug synthesis, complex formation and colloidal lipid carrier-based strategies have been developed for the delivery of drugs to intestinal lymphatics. In addition, polymeric nanoparticles, self-emulsifying delivery systems, liposomes, microemulsions, micellar solutions and recently, solid lipid nanoparticles (SLN) have been exploited as probable possibilities as carriers for oral intestinal lymphatic delivery.
Sources: en.wikipedia.org
== Function in Disease and Immunity and Clinical Relevance == Reticular cells do far more than support immune cells. They actively shape immune responses during disease and repair. As mentioned previously, their combined role in structure and signaling makes them crucial in both innate and adaptive immunity. Li et al. (2021) explain that fibroblastic reticular cells in lymph nodes organize structure, recruit immune cells, and present antigens. Additionally, it has been shown that they also induce interactions between dendritic cells, macrophages, and lymphocytes. This type of organization performed by the reticular cells ensures that immune reactions occur in the correct sequence, facilitating that a proper response happens. In a pathological environment, reticular cells adapt to regulate inflammation and tissue remodeling. For instance, when in chronic infection or autoimmune disorders, delayed activation of reticular cells can alter lymph node structure and either inhibit or intensify immune responses. Mueller and Germain (2015) found that excessive signaling from reticular cells contributes to immune dysregulation, leading to disorders in the body such as fibrosis. Conversely, it has been shown that controlled activation can actually enhance immune protection. Recent research also links fibroblastic reticular cells to anti-tumor immunity. In a 2025 Cell study, Onder et al. discovered that reticular cells located near tumors in lung cancer generate unique environments that allow cytotoxic T cells to infiltrate deeper into the cancer.
== Book chapters == 1. Richoz O, Hafezi F Modifications for Thin Corneas, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 51–55. 2. Hafezi F, Mavrakanas N Corneal Collagen Cross-Linking for Postoperative Corneal Ectasia, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 75–81. 3. Pajic B, Latinovic S, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Fankhauser F Lamellar corneal resection with LDV Crystal line femtosecond laser after penetrating keratoplasty, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 4. Pajic B, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Mueller J, Pajic D, Fankhauser F Applanation-free femtosecond laser processing of the cornea, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 5. Iseli HP, Hafezi F, Mrochen M, Seiler T Estado actual de la reticulación del colágeno corneal, in Técnicas de modelado corneal: desde la ortoqueratologia hasta el cross-linking, Cezón Prieto J, Editor. 2009, Sociedad Española de Cirurgia Ocular Implanto-Refractiva: Madrid. 381–86. 6. Hafezi F, Iseli HP, Seiler T Automated anterior lamellar keratoplasty for the management of complications in refractive surgery, in Surgical techniques in anterior and posterior lamellar corneal surgery, John T, Editor. 2005, Slack Inc.: New York. (in press). 7.
The corneal stroma consists of approximately 200 layers of mainly type I collagen fibrils. Each layer is 1.5-2.5 μm. Up to 90% of the corneal thickness is composed of stroma. There are 2 theories of how transparency in the cornea comes about: The lattice arrangements of the collagen fibrils in the stroma. The light scatter by individual fibrils is cancelled by destructive interference from the scattered light from other individual fibrils. The spacing of the neighboring collagen fibrils in the stroma must be < 200 nm for there to be transparency. (Goldman and Benedek) Descemet's membrane (also posterior limiting membrane): a thin acellular layer that serves as the modified basement membrane of the corneal endothelium, from which the cells are derived. This layer is composed mainly of collagen type IV fibrils, less rigid than collagen type I fibrils, and is around 5-20 μm thick, depending on the subject's age. Just anterior to Descemet's membrane, a very thin and strong layer, Dua's layer, 15 microns thick and able to withstand 1.5 to 2 bars of pressure. Corneal endothelium: a simple squamous or low cuboidal monolayer, approx 5 μm thick, of mitochondria-rich cells. These cells are responsible for regulating fluid and solute transport between the aqueous and corneal stromal compartments. (The term endothelium is a misnomer here. The corneal endothelium is bathed by aqueous humor, not by blood or lymph, and has a very different origin, function, and appearance from vascular endothelia.) Unlike the corneal epithelium, the cells of the endothelium do not regenerate.
Between 2005 and 2007, a Half-Life prequel was in development by Junction Point Studios, with a team led by Warren Spector. The game's plot was intended to explain the backstory behind both Ravenholm and Grigori, showing how it was attacked by the Combine and Grigori's actions prior to the player meeting him in Half-Life 2. It would have included a "magnet gun" which could attract metal objects from remote locations using metallic ball-shaped projectiles. In mid-2007, the project was cancelled and the studio went on to develop the platformer video game Epic Mickey instead, releasing it in 2010. The concept was later given to Arkane Studios, who changed it into a spinoff Half-Life game titled Ravenholm set entirely in the town, but was cancelled by Valve after "9 or 10" levels had already been completed. It was intended to feature Adrian Shephard, the protagonist of Half-Life: Opposing Force, as he made his way through the town with the help of Grigori. Grigori, revealed to have survived his last stand in Half-Life 2, would have gradually mutated into an inhuman being as the result of a serum created from headcrab blood that he believed would protect him from harm. The game would also have introduced several new weapons, such as a nail gun, which could power up doors by acting as an electrical conductor, a plasma weapon and a weaponized leaf blower that could be used to double jump.
Freeze-dried foods became a major component of astronaut and military rations. What began for astronaut crews as tubed meals and freeze-dried snacks that were difficult to rehydrate, were transformed into hot meals by improving the process of rehydrating freeze-dried meals with water. As technology and food processing improved, NASA looked for ways to provide a complete nutrient profile while reducing crumbs, disease-producing bacteria, and toxins. The crumb problem was solved with the addition of a gelatin coating on the foods to lock in and prevent crumbs. The complete nutrient profile was improved with the addition of an algae-based vegetable-like oil to add polyunsaturated fatty acids. Polyunsaturated fatty acids are beneficial in mental and vision development and, as they remain stable during space travel, can provide astronauts with added benefits. Disease-producing bacteria and toxins were reduced by quality control and the development of the Hazard Analysis and Critical Control Points (HACCP) plan, which is widely used today to evaluate food material before, during, and after processing. With the combination of these three innovations, NASA could provide safe and wholesome foods to their crews from freeze-dried meals. Military rations have also come a long way, from being served cured pork and corn meal to beefsteaks with mushroom gravy. How rations are chosen and developed is based on acceptance, nutrition, wholesomeness, producibility, cost, and sanitation.
Sources: en.wikipedia.org
Casamino acid is the mixture of amino acids produced from acid hydrolysis of casein, a family of phosphoproteins found in mammalian milk. In comparison, tryptone describes casein that has undergone enzymatic degradation by the protease trypsin, leaving many smaller peptide chains alongside the free amino acids. Casamino acid is used as a component of microbiological growth medium to support protein synthesis. However, tryptophan, an essential amino acid, is lost while digesting the casein with strong acids. Providing this abundant source of nitrogen can alter the phenotype of microorganisms, such as bacterial species recognizing nutrient-rich media and reducing their motility, as compared to their typical environmental behaviors.
At constant temperature, the rate of carbon assimilation varies with irradiance, increasing as the irradiance increases, but reaching a plateau at higher irradiance. At low irradiance, increasing the temperature has little influence on the rate of carbon assimilation. At constant high irradiance, the rate of carbon assimilation increases as the temperature is increased. These two experiments illustrate several important points: First, it is known that, in general, photochemical reactions are not affected by temperature. However, these experiments clearly show that temperature affects the rate of carbon assimilation, so there must be two sets of reactions in the full process of carbon assimilation. These are the light-dependent 'photochemical' temperature-independent stage, and the light-independent, temperature-dependent stage. Second, Blackman's experiments illustrate the concept of limiting factors. Another limiting factor is the wavelength of light. Cyanobacteria, which reside several meters underwater, cannot receive the correct wavelengths required to cause photoinduced charge separation in conventional photosynthetic pigments. To combat this problem, Cyanobacteria have a light-harvesting complex called Phycobilisome. This complex is made up of a series of proteins with different pigments which surround the reaction center.
== Limitations == With radioligand therapy, there is always the risk of damage to non-cancerous surrounding tissues along with radioisotope toxicity which is always a challenge in determining how to administer and create the radioligand. Furthermore, the radioligand vial is only viable for a limited time and under specific conditions which challenges transport and storage along with feasible application to the patient. Another limitation is the lack of centers that have trained personnel and equipment for radioligand therapy. Furthermore, individual characteristics affect the exact radiosensitivity to the therapy (thus affecting dosimetry) and are hard to predict without radiobiological models.
A placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the treatment's effectiveness. (NLM) An inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo. (NCI) Placebo controlled study
=== Writing === During an interview at the Deadline Hollywood, Kripke teased that the season would be exploring Vought's past to explore the myths surrounding the company and the United States in general, as the comics also explored flashbacks focused during World War II and the Vietnam War and wanted to explore over how the superhero phenomenon did not only altered the present but also parts from the past as well, while also exploring over how the politics can turn neighbors against each other and what actually means to be in America. He revealed that this was one of the reasons of introducing Soldier Boy in the season, since the history of Vought and the US was explored through the character given that he was the first superhero ever and has been around since the Second World War. Kripke revealed that the toxic masculinity would be the real-life issue of the season and would also show how it would be affecting the main characters after many of them are pushed to the limit. He detailed over how the toxic masculinity was an ongoing issue that as by today continues affecting the lives of a lot of men, with many of them being targeted for not being considered ‘manly’ enough and over how this becomes very destructive to the society and organizations. This was the main reason of Soldier Boy being introduced as he represents the embodiment of the toxic masculinity which is an issue that the world still faces thanks to the older generations.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.